SEZL heads into the week after a Q1 earnings release with short sellers rebuilding positions into a rising stock — a setup that puts squeeze dynamics back on the table.
The short position is uncomfortably large for bulls. Short interest climbed to 27.5% of the free float on May 5, up from around 25.4% in late April. That's a meaningful rebuild: shorts had trimmed exposure through mid-April as the stock found support, but the past two weeks have seen a steady reversal of that retreat. The cost to borrow jumped sharply this week — nearly doubling from 0.58% to 0.95% in two sessions — its highest level since at least late March. Borrow availability has tightened alongside the cost move. The lending pool is meaningfully less loose than it was a fortnight ago, though not yet in extreme squeeze territory. The ORTEX short score now reads 75.3, its highest print in the 10-day window, pointing to elevated short pressure relative to the broader universe.
Options positioning adds another layer. The put/call ratio is running at 0.70, modestly above its 20-day average of 0.67 — roughly half a standard deviation elevated. That's not a panic signal. But framed against the 52-week low of 0.06, the current reading shows that hedging demand has normalised after a prolonged period of unusual bullishness in the options market. Calls still dominate the options book, but the gap has narrowed.
Analyst coverage remains thin and tilts bullish. Keefe, Bruyette & Woods initiated with an Outperform in early April at a $85 target — essentially the current price. Needham holds a Buy with a $94 target, raised in February after reaffirming conviction post-earnings. TD Cowen sits on the sidelines at Hold, $82. Oppenheimer's Outperform with a $202 target dates to mid-2025 and likely reflects a substantially different price environment; that figure should be treated with caution given the stock's significant repricing since. The more actionable cluster of 2026 initiations sets a fair-value range of roughly $82–$94, bracketing the current price of $85.19 on the tighter end. The stock's trailing P/E of 16.7x has expanded nearly 3 turns over the past month — a meaningful re-rating for a payments name — though EV/EBITDA at 11.1x has actually eased slightly. EPS momentum ranks in the 82nd percentile on a 90-day basis, with an 81st-percentile EPS surprise score, suggesting the fundamental delivery has been the engine driving the multiple higher.
The institutional picture is being reshaped by large passive buyers. BlackRock added over 1.26 million shares in the most recent reporting period, bringing its stake to 7.5% of shares. State Street and T. Rowe Price also added. Founder and CEO Charles Youakim holds 43.7% of the company, providing significant insider alignment — but both he and co-founder Paul Paradis sold shares in early April around $63.70. Those transactions look routine in size (Youakim's was roughly $444k), and the stock is now trading 34% above those sale prices. CFO Lee Brading also sold in early April and simultaneously appears in the institutional holder table with a 320,851-share stake, suggesting the April sells were part of a scheduled programme rather than a conviction shift.
The Q1 earnings event is already in the books, announced as of today. The last earnings print with a recorded reaction — February's — knocked the stock down 10.5% on the day and 13.3% over the subsequent week. That reaction makes the current short rebuild more legible: with the stock up 33% over the past month, short sellers appear to be positioning for a mean-reversion trade against an earnings-driven multiple expansion. Peer AFRM gained 5.8% on the week and FLYW added 7.0%, suggesting the payments space broadly moved higher, which may have provided cover for shorts to add rather than capitulate. What to watch next: whether the fresh cost-to-borrow spike and continued short rebuilding persist after the earnings announcement clears, or whether short covering provides the next leg of upward pressure on the stock.
See the live data behind this article on ORTEX.
Open SEZL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
